Evolocumab biosimilar is under clinical development by Cinnagen and currently in Phase III for Hyperlipidemia. According to GlobalData, Phase III drugs for Hyperlipidemia have a 42% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Evolocumab biosimilar’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Evolocumab biosimilar overview
Evolocumab biosimilar is under development for the treatment of hyperlipidemia. The therapeutic candidate is administered through subcutaneous route. It acts by targeting PCSK9.
Cinnagen overview
Cinnagen is a biotechnology products provider that markets various molecular biology, biopharmaceuticals and diagnostic products. The company provides services such as technology transfer, export and market development programs. It offers market development programs such as out-licensing, in-licensing, supply and distribution, agency, technology transfer, research and development partnering, joint-venture, contract manufacturing and acquisitions and investment programs, among others. CinnaGen provides biosimilars, peptide-based therapeutics, therapeutic enzymes, monoclonal antibodies and recombinant proteins, among others. The company exports products across Asian, African and Latin American countries. CinnaGen is headquartered in Tehran, Iran.
For a complete picture of Evolocumab biosimilar’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
